Abstract: A method for producing an optically active compound includes reacting a nucleophile with a mixture of R- and S-stereoisomers of an azolide substrate by enzyme-catalyzed kinetic resolution so as to produce the optically active compound, wherein the azolide substrate contains an azole group used as a leaving group and an acyl group directly bonded to a nitrogen atom of the azole group.

Abstract: A new blood unit cooling system was designed to cool blood rapidly to about 22° C. and maintain it at about that temperature, even in ambient temperature extremes, for several hours. The system incorporating a preferred eutectic solution including 98% 1-dodecanol, 1.5% myristyl alcohol and 0.5% 1-decanol (having, a melting point of about 23° C.) contained in a sealed flexible polymer layer, was used to cool whole blood-filled bags. The preferred design uses inner and outer containers, each made of transparent polyethylene sheets, where the inner compartments are filled with the solution and sealed, and then placed into each compartment in an outer container, wherein two compartments in the outer container are separated by a flattened and sealed portion of the polyethylene.

Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.

Abstract: Cosmetic composition comprising at least one compound from advanced glycation end products (‘AGEs’) and/or precursors thereof as an agent for skin treatment, especially for protection and/or care of the skin. The present invention further provides a cosmetic composition comprising at least one compound from the group of the AGEs and/or precursors thereof, wherein the AGEs are prepared by reacting sugars with the amino acids lysine and/or arginine.

Abstract: The present invention provides novel aryl pyrrolidines having an excellent insecticidal action as insecticides. Aryl pyrrolidines represented by the formula (I) and use thereof as insecticide.

Abstract: A cosmetic composition is provided including a water-insoluble UV-A sunscreen agent having a ?max at 330-380 nm, a water-insoluble UV-B sunscreen agent having a ?max between 280 and 320 nm, and a water-soluble sunscreen agent having a ?max between 280 and 400 nm, the water-soluble sunscreen agent being neutralized with metallic counter ions which in a first portion are sodium and in a second portion are potassium ions present in a respective molar ratio of 0.5:2 to 2:1, and a cosmetically acceptable carrier including from 0.2 to 4% of potassium stearate by weight of the composition.

Abstract: Engineered particles are provided may be used for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is ? times by mass to 4 times by mass as that of the rosin-based resin.

Abstract: The invention relates to novel bicyclononene derivatives of Formula (I); and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

Abstract: The present invention provides a nutritional composition and a pharmaceutical composition to be used for humans or animals comprising as active compound the oleuropein compound or one derivative thereof.

Abstract: This invention discloses a process for making nanopanticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in an nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired.

Abstract: Matrix controlled diffusion drug delivery systems based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.

Abstract: Matrix controlled diffusion drug delivery systems are described herein which are based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.

Abstract: The invention relates to 5-(substituted dithio- or dioxy-alkylamino)pyrazole derivatives of formula (I) or salts thereof: wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections.

Abstract: The present invention relates generally to medical devices, preferably a stent, having a drug eluting surface coated or covered with a coating of particles comprising at least an outer layer, an inner layer, and a core comprising a therapeutic agent. Specifically, the invention relates to medical devices having a hydrophilic coating comprising particles with a hydrophilic outer layer, a hydrophobic inner layer, and a core comprising a hydrophobic therapeutic agent, as well as medical devices having a hydrophobic coating comprising particles with a hydrophobic outer layer, a hydrophilic inner layer, and a core comprising a hydrophilic therapeutic agent. The coating, outer layer, and inner layer are preferably biodegradable and capable of providing sustained release of the therapeutic agent over a time period. The invention also relates to methods of making and methods of using the coated or covered medical device.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: The present invention relates to novel active compound combinations comprising a known oxime ether derivative (trifloxystrobin) and imidacloprid, which combinations are highly suitable for controlling phytopathogenic fungi and insects.